A phase III trial (OlympiA) is currently ongoing to assess OS in patients with HER2-negative breast cancer with germline BRCA mutations treated with the PARP inhibitor Olaparib in the adjuvant setting (NCT02032823). Here, ERBB2 is linked to breast cancer.